NCT01890759View on ClinicalTrials.gov

Immunogenicity and Safety of Menactra® Vaccine in Subjects Aged 9 to 23 Months in India and in the Russian Federation

PHASE3CompletedINTERVENTIONAL

Enrollment

300

Participants

Timeline

Start Date

June 25, 2013

Primary Completion Date

April 12, 2016

Study Completion Date

April 12, 2016

Conditions

MeningitisMeningococcal Infection

Interventions

BIOLOGICAL

Meningococcal Diphtheria Toxoid Vaccine

0.5 mL, Intramuscular

Trial Locations (8)

183031

Murmansk

197022

Saint Petersburg

226003

Lucknow

390022

Vadodara

614066

Perm

620028

Yekaterinburg

632004

Vellore

700017

Kolkata

All Listed Sponsors

lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT01890759 - Immunogenicity and Safety of Menactra® Vaccine in Subjects Aged 9 to 23 Months in India and in the Russian Federation | Biotech Hunter | Biotech Hunter